Johnson & Johnson Stock News

A senior official at Nigeria's drug regulator said on Tuesday that the regulator had no record of children dying from a batch of cough syrup manufactured by Johnson & Johnson which had been recalled.

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.68 per share a year ago.

Its products are sold under these brands: Exxon Esso Mobil  The Chemical Products segment manufactures and markets petrochemicals, including olefins, polyolefins, and intermediates.

Johnson & Johnson CFO Joseph Wolk joins ‘Squawk Box' to discuss the company's quarterly earnings results that topped Wall Street's expectations.

Johnson & Johnson's stock JNJ, +0.05% fell 0.4% early Tuesday, after the healthcare company posted better-than-expected profit for the first quarter but sales that fell slightly short of expectations.

The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.

Johnson & Johnson reported a first-quarter profit above Wall Street estimates on Tuesday, helped by strong sales of its cancer drugs including top-selling blood cancer treatment Darzalex.

Jared Holz, Mizuho, joins 'Fast Money' to talk what to expect from the upcoming slate of health care earnings.

Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Johnson & Johnson stock (NYSE: JNJ) will report its Q1 2024 results on Tuesday, April 16. We expect the company to post revenue of $21.5 billion and earnings of $2.68, compared to the consensus estima

Pharmaceuticals firm Johnson & Johnson kicks off earnings season for the sector on Tuesday. Investors want executives to put to rest ongoing talc litigation.

Blue Chip stocks to watch in the stock market today.

We have narrowed our search to five large-cap stocks that are poised to beat on earnings results this week. These are: BAC, JNJ, UAL, PNC, BK.

Rwanda's drug regulator has recalled a batch of Johnson & Johnson children's cough syrup as a precautionary measure after its Nigerian counterpart said laboratory tests found high levels of toxicity.

The S&P 500 is doing great this year after last year's historic run higher. The broad index is up almost 9% in 2024.